Corcept Therapeutics (CORT) Liabilities and Shareholders Equity (2010 - 2026)

Corcept Therapeutics has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $814.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $814.9 million, down 3.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 billion (up 2.86% YoY), and the FY2025 annual result was $836.7 million, changed 0.46% from the prior year.
• Liabilities and Shareholders Equity came in at $814.9 million for Q1 2026 at Corcept Therapeutics, down from $836.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $846.5 million in Q1 2025 to a low of $468.1 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $655.9 million (2024), against an average of $679.9 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 37.68% in 2022, while the deepest fall reached 15.26% in 2022.
• Corcept Therapeutics' Liabilities and Shareholders Equity stood at $583.4 million in 2022, then advanced by 6.53% to $621.5 million in 2023, then surged by 35.24% to $840.6 million in 2024, then decreased by 0.46% to $836.7 million in 2025, then declined by 2.6% to $814.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $814.9 million (Q1 2026), $836.7 million (Q4 2025), and $823.6 million (Q3 2025), per Business Quant data.